Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -5.01
- Piotroski Score 3.00
- Grade Neutral
- Symbol (ICPT)
- Company Intercept Pharmaceuticals, Inc.
- Price $19.00
- Changes Percentage (0.21%)
- Change $0.04
- Day Low $18.98
- Day High $19.01
- Year High $21.86
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/05/2023
- Fiscal Year End N/A
- Average Stock Price Target $19.00
- High Stock Price Target $44.00
- Low Stock Price Target $10.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.09
- Trailing P/E Ratio -17.43119266055
- Forward P/E Ratio -17.43119266055
- P/E Growth -17.43119266055
- Net Income $115.17 M
